Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Neurocrine (NBIX) and Castle Biosciences (CSTL).
Neurocrine (NBIX)
Mizuho Securities analyst Vamil Divan maintained a Hold rating on Neurocrine yesterday and set a price target of $117.00. The company’s shares closed last Monday at $102.81.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.8% and a 44.3% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and Revance Therapeutics.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Neurocrine with a $134.25 average price target.
See today’s analyst top recommended stocks >>
Castle Biosciences (CSTL)
In a report released yesterday, Max Masucci from Canaccord Genuity maintained a Buy rating on Castle Biosciences, with a price target of $61.00. The company’s shares closed last Monday at $47.78.
According to TipRanks.com, Masucci is a 5-star analyst with an average return of 57.4% and a 75.0% success rate. Masucci covers the Healthcare sector, focusing on stocks such as Genetron Holdings, Guardant Health, and Exact Sciences.
Castle Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $62.00, implying a 23.0% upside from current levels. In a report issued on October 30, BTIG also maintained a Buy rating on the stock with a $60.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
